Sunday, October 02, 2016 9:18:15 PM
In reviewing recent press releases, in April, the company outlined the steps needed for clinical trial. In May they had press giving an update of progress towards clinical trial. They have also been working with the University of Alberta the last few years and the studies have been on the use of AAGP for organ transplants, rheumatoid arthritis, multiple sclerosis and Type 1 diabetes. So, this appears to be a company headed to clinical trials in the next 12 months. Stock is currently trading at .07 and a modest market cap of $16 million, it looks like a good time to begin accumulating.
Recent PKTX News
- Form D/A - Notice of Exempt Offering of Securities: [Amend] • Edgar (US Regulatory) • 05/15/2024 09:14:59 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 12:46:59 PM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM